Anavex Life Sciences Corp. (AVXL) financial statements (2020 and earlier)

Company profile

Business Address 51 W 52ND STREET,
NEW YORK, NY 10019-6163
State of Incorp. NV
Fiscal Year End September 30
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2223279157
Cash and cash equivalents2223279157
Receivables3     
Prepaid expense 10000
Other undisclosed current assets10000 
Total current assets:2524289157
Noncurrent Assets
Property, plant and equipment    00
Deposits noncurrent assets 000  
Total noncurrent assets: 00000
TOTAL ASSETS:2524289157
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:544331
Accounts payable4     
Accrued liabilities2     
Other undisclosed accounts payable and accrued liabilities 44331
Debt    00
Other undisclosed current liabilities   00 
Total current liabilities:544331
Noncurrent Liabilities
Long-term debt and lease obligation    0 
Long-term debt, excluding current maturities    0 
Other undisclosed noncurrent liabilities     6
Total noncurrent liabilities:    06
Total liabilities:544337
Stockholders' equity
Stockholders' equity attributable to parent, including:2020246130
Common stock000000
Common stock, value, subscriptions     1
Additional paid in capital154129116847452
Accumulated deficit(133)(109)(91)(78)(63) 
Receivable from officers and directors for issuance of capital stock    2 
Other undisclosed stockholders' equity attributable to parent     (53)
Total stockholders' equity:2020246130
TOTAL LIABILITIES AND EQUITY:2524289157

Income statement (P&L) ($ in millions)

9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
Operating expenses(29)(19)(16)(16)(7)(5)
Other undisclosed operating income     2
Operating loss:(29)(19)(16)(16)(7)(3)
Nonoperating income (expense)3221(5)(8)
Investment income, nonoperating     (9)
Debt instrument, convertible, beneficial conversion feature    7 
Interest and debt expense0(0) 00(9)
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)     
Loss from continuing operations before equity method investments, income taxes:(26)(17)(13)(15)(12)(20)
Other undisclosed income (loss) from continuing operations before income taxes 0 (0)(0) 
Loss from continuing operations before income taxes:(26)(17)(13)(15)(12)(20)
Income tax expense(0)(0)(0)(0)  
Net loss:(26)(17)(13)(15)(12)(20)
Other undisclosed net income attributable to parent     9
Net loss available to common stockholders, diluted:(26)(17)(13)(15)(12)(11)

Comprehensive Income ($ in millions)

9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
Net loss:(26)(17)(13)(15)(12)(20)
Comprehensive loss, net of tax, attributable to parent:(26)(17)(13)(15)(12)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: